4 May 2026: NHS Cancer Jab Cuts Treatment Time by 90%
The NHS rolls out a one-minute cancer jab replacing lengthy IV drips, cutting treatment time by up to 90% for tens of thousands of UK patients.
4 May 2026 News Roundup: A Faster Future for NHS Cancer Treatment
On Monday, 4 May 2026, a landmark development in NHS cancer care is making headlines across the UK. A new one-minute injectable form of a widely used immunotherapy drug is being rolled out to tens of thousands of patients, dramatically cutting the time people spend in hospital receiving treatment. The story speaks to a broader shift in how the NHS is working to modernise care pathways — reducing the burden on patients and clinical staff alike, while continuing to bring down waiting times. Here's what caught our attention.
Tens of Thousands Could Benefit From One-Minute Cancer Jab Rolled Out on the NHS
The NHS has begun rolling out a rapid new injectable form of the immunotherapy drug pembrolizumab (Keytruda), which can be administered in as little as one minute — replacing intravenous drip sessions that previously took up to 30–60 minutes or more. The new subcutaneous injection reduces patient treatment time by up to 90 per cent and cuts the time NHS pharmacy and clinical staff spend preparing the drug by an estimated 44 per cent, according to analysis by manufacturer MSD. Pembrolizumab works by blocking a protein called PD-1, which acts as a brake on immune responses, effectively releasing the immune system to recognise and attack cancer cells — and it is already used across a wide range of cancer types in the UK. Among the first patients to receive the new jab on the NHS was 89-year-old Shirley Xerxes from St Albans, who is being treated for bowel cancer, highlighting how this innovation is already reaching real patients in everyday NHS settings. Health and Social Care Secretary Wes Streeting, himself a cancer survivor, welcomed the rollout, saying the change would offer "quicker, more convenient care, saving patients time and helping them in their recovery with less time in hospital." Professor Peter Johnson, NHS national clinical director for cancer, echoed this sentiment, noting that the innovation would free up vital appointments and help NHS teams treat more people. For the tens of thousands of patients receiving pembrolizumab in the UK each year, this change could mean fewer gruelling hours in clinical settings and a meaningfully improved quality of life during treatment.
Source: independent.co.uk
Today's Takeaway
Today's news is a reminder that progress in medicine is not always about discovering entirely new treatments — sometimes it is about making existing, proven therapies easier to deliver and less disruptive to live with. The shift from intravenous drip to a one-minute subcutaneous injection for pembrolizumab may seem like a logistical footnote, but for a patient sitting in a chemotherapy ward for the third time that month, it is transformative. In the UK, where NHS capacity remains under pressure, innovations that simultaneously improve patient experience and free up clinical time are not just welcome — they are essential.
96 Bacterial Strains. Two Shots a Day.
GOODIE is an award-winning fermented drink with 96 live bacterial strains — more than any yogurt or kombucha — never pasteurised, clinically tested, and 8 in 10 users felt less bloating within 14 days. Curious?